World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0037152764
Reproduction Date:

Title: Mirabegron  
Author: World Heritage Encyclopedia
Language: English
Subject: Overactive bladder, Astellas Pharma, Solifenacin, Broxaterol, Mivazerol
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Trade names Myrbetriq (US), Betanis (Japan), Betmiga (EU)
Licence data EMA:, US FDA:
Pregnancy cat.
Legal status
Routes Oral
Pharmacokinetic data
Bioavailability 29-35%[1]
Protein binding 71%[1]
Metabolism Hepatic via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase[1]
Half-life 50 hours[1]
Excretion Urine (55%), faeces (34%)[1]
CAS number
ATC code G04
Synonyms YM-178
Chemical data
Formula C21H24N4O2S 
Mol. mass 396.506 g/mol

Mirabegron (formerly YM-178, trade name Myrbetriq, Betmiga in Spain) is a drug for the treatment of overactive bladder.[2] It was developed by Astellas Pharma and was approved in the United States in July 2012.[3]

Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.[4]

Medical uses

Its primary use is in the treatment of overactive bladder.[1][5][6]

Adverse effects

Adverse effects by incidence:[1][5][6]

Very common (>10% incidence) adverse effects include:

  • Elevated blood pressure

Common (1-10% incidence) adverse effects include:

Rare (<1% incidence) adverse effects include:

  • Palpitations
  • Blurred vision
  • Glaucoma
  • Dyspepsia (indigestion)
  • Gastritis
  • Abdominal distension
  • Rhinitis
  • Elevations in liver enzymes (GGT, AST, ALT & LDH)
  • Renal and urinary disorders (e.g., nephrolithiasis, bladder pain)
  • Reproductive system disorders (e.g., vulvovaginal pruritis, vaginal infection)
  • Skin and subcutaneous tissue disorders (e.g., urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema)
  • Stevens-Johnson syndrome associated with increased serum ALT, AST and bilirubin
  • Urinary retention


  1. ^ a b c d e f g "mirabegron (Rx) - Myrbetriq". Medscape Reference. WebMD. Retrieved 17 November 2013. 
  2. ^ Gras, J (2012). "Mirabegron for the treatment of overactive bladder". Drugs of today (Barcelona, Spain : 1998) 48 (1): 25–32.  
  3. ^ Sacco E, Bientinesi R, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014 Apr;9(4):433-48. doi: 10.1517/17460441.2014.892923. Epub 2014 Feb 22.PMID 2455903
  4. ^ "New Drug Approvals 2012 - Pt. XIV - Mirabegron (MyrbetriqTM)".  
  5. ^ a b "MYRBETRIQ (mirabegron) tablet, film coated, extended release [Astellas Pharma US, Inc.]". DailyMed. Astellas Pharma US, Inc. September 2012. Retrieved 17 November 2013. 
  6. ^ a b "Betmiga 25mg & 50mg prolonged-release tablets". electronic Medicines Compendium. Astellas Pharma Ltd. 22 February 2013. Retrieved 17 November 2013. 

External links

  • Sacco, E.; Bientinesi, R. (2012). "Mirabegron: A review of recent data and its prospects in the management of overactive bladder". Therapeutic Advances in Urology 4 (6): 315–24.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.